CLINICAL RESEARCH: HEART FAILURE
Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy
Hitoshi Yamaguchi, MD, PhD*, ,
Junichi Yoshida, MD ,,
Kazuhiro Yamamoto, MD, PhD, FACC,*,
Yasushi Sakata, MD, PhD,
Toshiaki Mano, MD, PhD,
Noriyuki Akehi, MD,
Masatsugu Hori, MD, PhD, FACC,
Young-Jae Lim, MD, PhD*,
Masayoshi Mishima, MD, PhD* and
Tohru Masuyama, MD, PhD, FACC
* Department of Cardiology, Kawachi General Hospital, Higashi-Osaka, Japan
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
Manuscript received April 4, 2003;
revised manuscript received June 12, 2003,
accepted July 29, 2003.
* Reprint requests and correspondence: Dr. Kazuhiro Yamamoto, Department of Internal Medicine and Therapeutics (A8), Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan.
kazuhiro{at}medone.med.osaka-u.ac.jp
OBJECTIVES: We tested a hypothesis that elevation of the plasma level of brain natriuretic peptide (BNP) is one of the characteristics of patients with diastolic heart failure (DHF) independent of left ventricular (LV) hypertrophy.
BACKGROUND: The clinical characteristics of DHF are not well acknowledged, although DHF has become a great social burden. Such a lack of clinical information leads to inaccuracy in the diagnosis of DHF. We have demonstrated enhancement of ventricular production of BNP with progression of maladaptive ventricular hypertrophy, but not with development of compensatory hypertrophy in an animal DHF model.
METHODS: Of 372 patients who presented to the emergency department because of acute pulmonary congestion without acute coronary syndrome between January 1996 and May 2002, those with an ejection fraction  45% upon admission, who were stably controlled at least for a year in our outpatient clinics, comprised the DHF group (n = 19). A control group consisted of 22 hypertensive patients with a LV mass index greater than or equal to its minimum value of the DHF group and an ejection fraction 45%, in whom cardiac symptoms had not occurred.
RESULTS: Despite a similar distribution of LV mass index, the BNP level was higher in the DHF group than in the control group (149 ± 38 vs. 31 ± 5 pg/ml, p < 0.01). There was no difference in LV cavity size or parameters derived from pulsed Doppler transmitral flow velocity curves.
CONCLUSIONS: An elevation of BNP may be a hallmark of patients with or at risk of DHF among subjects with preserved systolic function independent of LV hypertrophy.
|
Abbreviations and Acronyms
| | ANP | = atrial natriuretic peptide | | BNP | = brain natriuretic peptide | | DHF | = diastolic heart failure | | E/A | = ratio of peak mitral E-wave velocity to peak mitral A-wave velocity | | EF | = ejection fraction | | HF | = heart failure | | LV | = left ventricular | | NYHA | = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
R. W. Troughton and A. M. Richards
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Martos, J. Baugh, M. Ledwidge, C. O'Loughlin, N. F. Murphy, C. Conlon, A. Patle, S. C. Donnelly, and K. McDonald
Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover
Eur J Heart Fail,
February 1, 2009;
11(2):
191 - 197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herrmann, O. Taban-Shoma, U. Hubner, A. Pexa, H. Kilter, N. Umanskaya, R. Hans Straub, M. Bohm, and W. Herrmann
Hyperhomocysteinemia and Myocardial Expression of Brain Natriuretic Peptide in Rats
Clin. Chem.,
April 1, 2007;
53(4):
773 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ohtani, M. Ohta, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, Y. Takeda, J. Yoshida, T. Miwa, M. Okamoto, et al.
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker
Am J Physiol Regulatory Integrative Comp Physiol,
February 1, 2007;
292(2):
R946 - R954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herrmann, S. Muller, I. Kindermann, L. Gunther, J. Konig, M. Bohm, and W. Herrmann
Plasma B vitamins and their relation to the severity of chronic heart failure
Am. J. Clinical Nutrition,
January 1, 2007;
85(1):
117 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai
Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction
Angiology,
January 1, 2007;
57(6):
686 - 693.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Shelton, A. L. Clark, K. Goode, A. S. Rigby, and J. G.F. Cleland
The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation
Eur. Heart J.,
October 1, 2006;
27(19):
2353 - 2361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. McKie, R. J. Rodeheffer, A. Cataliotti, F. L. Martin, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, M. M. Redfield, and J. C. Burnett Jr
Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure
Hypertension,
May 1, 2006;
47(5):
874 - 880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Watanabe, J. Shite, H. Takaoka, T. Shinke, Y. Imuro, T. Ozawa, H. Otake, D. Matsumoto, D. Ogasawara, O. L. Paredes, et al.
Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure
Eur. Heart J.,
April 1, 2006;
27(7):
832 - 838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tschope, M. Kasner, D. Westermann, R. Gaub, W. C. Poller, and H.-P. Schultheiss
The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements
Eur. Heart J.,
November 1, 2005;
26(21):
2277 - 2284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, T. Ohtani, M. Hori, T. Miwa, and T. Masuyama
Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats
Cardiovasc Res,
October 1, 2005;
68(1):
118 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fiorina, C. Gremizzi, P. Maffi, R. Caldara, D. Tavano, L. Monti, C. Socci, F. Folli, F. Fazio, E. Astorri, et al.
Islet Transplantation Is Associated With an Improvement of Cardiovascular Function in Type 1 Diabetic Kidney Transplant Patients
Diabetes Care,
June 1, 2005;
28(6):
1358 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Souza, H. B. Bogossian, M. Humbert, C. Jardim, R. Rabelo, M. B. P. Amato, and C. R. R. Carvalho
N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension
Eur. Respir. J.,
March 1, 2005;
25(3):
509 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sharp and J. Mayet
Review: The utility of BNP in clinical practice
Journal of Renin-Angiotensin-Aldosterone System,
June 1, 2004;
5(2):
53 - 58.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. B. Mark and G. M. Felker
B-Type Natriuretic Peptide -- A Biomarker for All Seasons?
N. Engl. J. Med.,
February 12, 2004;
350(7):
718 - 720.
[Full Text]
[PDF]
|
|
|
|
